局灶视网膜激光光凝术联合阿柏西普眼内注射溶液经玻璃体腔注射治疗局灶型糖尿病性黄斑水肿的疗效  

Clinical Efficacy of Focal Retinal Laser Photocoagulation Combined with Aflibercept Intraocular Injection Solution in the Treatment of Focal Macular Edema in Diabetes

作　　者：徐象周 李泓彬[2] 翁宏武 张世华 陈子林[3] Xu Xiangzhou;Li Hongbin;Weng Hongwu;Zhang Shihua;Chen Zilin(Medicine Graduate School,Shantou University,Shantou Guangdong 515000,China;Huizhou First People's Hospital,Huizhou Guangdong 516000,China;Huizhou Central People's Hospital,Huizhou Guangdong 516000,China)

机构地区：[1]汕头大学医学院研究生院,广东汕头515000 [2]惠州市第一人民医院,广东惠州516000 [3]惠州市中心人民医院,广东惠州516000

出　　处：《医疗装备》2023年第6期1-4,共4页Medical Equipment

基　　金：2021年惠州市科技计划项目(2021WC0106246)。

摘　　要：目的 探讨局灶视网膜激光光凝术联合阿柏西普眼内注射溶液经玻璃体腔注射治疗局灶型糖尿病性黄斑水肿(DME)的临床效果。方法 选取惠州市第一人民医院2020年1月至2021年12月收治的48例局灶型DME患者,按随机数字表法分为两组,各24例。对照组予以阿柏西普眼内注射溶液经玻璃体腔注射治疗,试验组在对照组基础上加用局灶视网膜激光光凝术治疗,均随访36周,比较两组最佳矫正视力(BCVA)、黄斑情况、玻璃体腔药物注射次数及生命质量变化。结果 试验组治疗后BCVA、黄斑中心厚度(CMT)、黄斑区视网膜平均厚度(CAT)、黄斑总体积(TMV)、玻璃体腔药物注射次数为分别为(0.59±0.11)、(289.63±25.41)μm、(302.41±36.52)μm、(9.25±1.02)mm3、(5.36±1.02)次,均低于对照组的(0.75±0.19)、(342.47±31.52)μm、(341.14±38.41)μm、(10.37±1.42)mm3、(7.52±1.24)次,差异有统计学意义(P <0.05);试验组治疗后视功能损害眼病患者生命质量量表(SQOL-DVI)的临床症状和视功能、社会活动、身体机能、精神心理评分及总分分别为(55.63±5.12)分、(27.89±2.04)分、(30.14±2.78)分、(28.41±2.35)分、(142.05±12.13)分,均高于对照组的(50.41±5.05)分、(24.15±1.89)分、(27.69±2.25)分、(25.05±2.24)分、(127.31±10.52)分,差异有统计学意义(P<0.05)。结论 局灶视网膜激光光凝术联合阿柏西普眼内注射溶液经玻璃体腔注射可提高局灶型DME患者治疗效果,加快BCVA复常,改善黄斑水肿情况,减少玻璃体腔药物注射次数,降低疾病对患者生命质量的影响。Objective The clinical effect of focal retinal laser photocoagulation combined with Aflibercept intraocular injection solution through vitreous cavity in the treatment of focal diabetes macular edema(DME)was explored.Methods With selection of 48 patients with focal DME admitted to Huizhou First People's Hospital from January 2020 to December 2021,the patients were divided into two groups according to the method of random number table,with 24 patients in each group.With the control group treated with intravitreal injection of Aflibercept solution through vitreous cavity,and the observation group treated with focal retinal laser photocoagulation on the basis of the control group,the best corrected visual acuity (BCVA), macular condition, intravitreal drug injection times and quality of life of the twogroups were compared. Results After treatment, BCVA, central macular thickness (CMT), meanmacular retinal thickness (CAT), total macular volume (TMV) and intravitreal drug injection timesin the observation group were (0.59±0.11)、(289.63±25.41) μm, (302.41±36.52) μm, (9.25±1.02) mm3 and (5.36±1.02) times was lower than the control group (0.75±0.19), (342.47±31.52) μm, (341.14±38.41) μm, (10.37±1.42)mm3 and (7.52±1.24) times, and the differenceswere statistically significant (P < 0.05);After treatment, the clinical symptoms, visualfunction, social activity, physical function, mental state and total scores of the observationgroup were (55.63±5.12) points, (27.89±2.04) points, (30.14±2.78) points, (28.41±2.35)points, (142.05±12.13) points, which were higher than those of the control group (50.41±5.05) points, (24.15±1.89) points, (27.69±2.25) points, (25.05±2.24) points, (127.31±10.52) points, and the differences were statistically significant (P< 0.05). Conclusion Focal retinallaser photocoagulation combined with intravitreal injection of Aflibercept solution through vitreouscavity can improve the treatment effect of patients with focal DME, accelerate the normalization ofBCVA, improve macular ed

关 键 词：糖尿病性黄斑水肿 视网膜激光光凝术 阿柏西普眼内注射溶液 最佳矫正视力 

分 类 号：R587.2[医药卫生—内分泌]